Lupin Partners with Cost Plus Drugs & COPD Foundation to expand access to medication for COPD Patients

India Pharma Outlook Team | Friday, 08 September 2023

 India Pharma Outlook Team

Lupin Limited (Lupin) has formed a unique partnership with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a pioneer in cheap pharmaceuticals, and the COPD Foundation, which is dedicated to improving the lives of COPD sufferers. This collaboration intends to improve access to healthcare by making tiotropium bromide inhalation powder, 18 mcg/capsule, available to COPD patients in the United States. Lupin's tiotropium bromide inhalation powder, 18 mcg/capsule is currently the only generic medicine available that is medically similar to Boehringer Ingelheim Pharmaceuticals, Inc.'s Spiriva HandiHaler (tiotropium bromide inhalation powder), 18 mcg/capsule.

Chronic obstructive pulmonary disease (COPD) affects approximately 15 million adults in the United States and is the country's fourth largest cause of mortality. This agreement is a crucial step towards reducing disease burden by improving patient access to products in the United States. "We believe there is a large unmet need for improved and affordable products for patients in the US," said Spiro Gavaris, president of Lupin's US generics. With our respiratory portfolio and pipeline, we are committed to enhancing patient access and seeking therapeutic alternatives for respiratory illnesses such as COPD. Our work with Mark Cuban Cost Plus Drug Company and the COPD Foundation demonstrates our commitment to provide patients with high-quality treatment alternatives."

"We are very excited to be working with Lupin and the COPD Foundation to bring lower prescription drug prices to consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. "Cost Plus Drugs, Lupin, and the COPD Foundation all have the same goal in mind: to provide customers with the lowest possible price for their prescription medication." Consumers may be confident that they are obtaining a fair price and the convenience of having medication shipped straight to their homes when they use Cost Plus Drugs." “Accessible and affordable medications are a pathway to a healthier, more empowered life for COPD patients,” said Jean Wright, M.D., CEO of the COPD Foundation. “Breathing freely shouldn’t come at the cost of financial strain. Having a generic option will ensure that vital treatments remain within reach, allowing patients to prioritize their health.”

The Mark Cuban Cost Plus Drug Company, PBC aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just `as important as the bottom line. Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

© 2024 India Pharma Outlook. All Rights Reserved.